DrugPatentWatch Database Preview
Moxidectin - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic sources for moxidectin and what is the scope of patent protection?
Moxidectin
is the generic ingredient in one branded drug marketed by Mdgh and is included in one NDA. Additional information is available in the individual branded drug profile pages.There is one drug master file entry for moxidectin. One supplier is listed for this compound.
Summary for moxidectin
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 61 |
| Clinical Trials: | 14 |
| Patent Applications: | 3,261 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | moxidectin at DailyMed |
Recent Clinical Trials for moxidectin
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Institut National de la Santé Et de la Recherche Médicale, France | Phase 2 |
| Medicines Development Limited | Phase 3 |
| National Institute of Public Health, Vientiane, Laos | Phase 2 |
Synonyms for moxidectin
| (2aE,2'R,4E,4'E,5'S,6R,6'S,8E,11R,15S,17aR,20R,20aR,20bS)-6'-[(1E)-1,3-Dimethylbut-1-enyl]-20,20b-dihydroxy-4'-(methoxyimino)-5',6,8,19-tetramethyl-3',4',5',6,6',7,10,11,14,15,17a,20,20a,20b-tetradeca |
| (6R,23E,25S)-5-O-Demethyl-28-deoxy-25-[(1E)-1,3-dimethyl-1-buten-1-yl]-6,28-epoxy-23-(methoxyimino)milbemycin B |
| (6R,25S)-5-O-Demethyl-28-deoxy-25-((E)-1,3-dimethyl-1-butenyl)-6,28-epoxy-23-oxomilbemycin B 23-(E)-(O-methyloxime) |
| [6R,23E,25S(E)]-5-O-Demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino)milbemycin B |
| 113507-06-5 |
| 119718-45-5 |
| 23-Methoxime-LL-F 28249|A |
| 507M065 |
| AB0021112 |
| AB01563071_01 |
| AC-27773 |
| AK323650 |
| AKOS015895074 |
| AKOS025401990 |
| AN-33358 |
| AOB6815 |
| AS-16969 |
| AS-17881 |
| BCP07263 |
| C37H53NO8 |
| CAS-113507-06-5 |
| CCG-213416 |
| CHEMBL1867915 |
| CHEMBL2104415 |
| CL-301423 |
| CL301423 |
| CS-3080 |
| Cydectin |
| D05084 |
| DA-47802 |
| DSSTox_CID_17577 |
| DSSTox_GSID_37577 |
| DSSTox_RID_79341 |
| DTXSID5037577 |
| EBD11520 |
| Equest |
| EX-A496 |
| HMS3264I15 |
| HY-B0777 |
| hydrospiro[2H,17H-11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-17-one |
| I06-0481 |
| LS-172228 |
| MFCD00866560 |
| milbemycin B of milbemycin |
| Milbemycin B, 5-O-demethyl-28-deoxy-25-((1E)-1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino)-, (6R,23E,25S)- |
| Milbemycin B, 5-O-demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino)-, (6R,23E,25S(E))- |
| Milbemycin B, 5-O-demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino)-, (6R,23Z,25S(E))- |
| Moxidectin (USAN/INN) |
| Moxidectin [USAN:INN:BAN] |
| Moxidectin [USAN:INN] |
| Moxidectin for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Moxidectin for veterinary use impurity L [EP] |
| Moxidectin impurity L |
| Moxidectin, (23Z)- |
| Moxidectin, European Pharmacopoeia (EP) Reference Standard |
| Moxidectin, Pharmaceutical Secondary Standard; Certified Reference Material |
| Moxidectin, United States Pharmacopeia (USP) Reference Standard |
| Moxidectin, VETRANAL(TM), analytical standard |
| Moxidectina |
| Moxidectina [INN-Spanish] |
| Moxidectine |
| Moxidectine [INN-French] |
| Moxidectinum |
| Moxidectinum [INN-Latin] |
| NCGC00182083-02 |
| NCGC00183118-01 |
| NGU5H31YO9 |
| NSC-760424 |
| NSC760424 |
| Pharmakon1600-01505394 |
| ProHeart 6 |
| Quest |
| SCHEMBL118876 |
| SCHEMBL12554967 |
| SCHEMBL13112872 |
| SCHEMBL3462914 |
| SR-05000002058 |
| SR-05000002058-1 |
| Tox21_113093 |
| Tox21_113389 |
| TYC529328W |
| UNII-NGU5H31YO9 |
| UNII-TYC529328W |
| V2325 |
| Vetdectin Oral Drench |
| YZBLFMPOMVTDJY-LSGXYNIPSA-N |
| YZBLFMPOMVTDJY-UBOCAARVSA-N |
| ZINC169649308 |
| ZINC253476173 |
US Patents and Regulatory Information for moxidectin
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mdgh | MOXIDECTIN | moxidectin | TABLET;ORAL | 210867-001 | Jun 13, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Mdgh | MOXIDECTIN | moxidectin | TABLET;ORAL | 210867-001 | Jun 13, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
